Now showing items 1-5 of 5
Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry.
(J Am Heart Assoc, 2013-07-18)
BACKGROUND: The prevalence of atrial fibrillation (AF) continues to increase; however, there are limited data describing the division of care among practitioners in the community and whether care differs depending on provider ...
Delays in appropriate antibiotic therapy for gram-negative bloodstream infections: a multicenter, community hospital study.
(PLoS One, 2013)
BACKGROUND: Gram-negative bacterial bloodstream infection (BSI) is a serious condition with estimated 30% mortality. Clinical outcomes for patients with severe infections improve when antibiotics are appropriately chosen ...
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.
(J Am Heart Assoc, 2013-11-25)
BACKGROUND: Dabigatran is a novel oral anticoagulant approved for thromboprophylaxis in atrial fibrillation. Adoption patterns of this new agent in community practice are unknown. METHODS AND RESULTS: We studied patterns ...
Gender and age interact to affect early outcome after intracerebral hemorrhage.
(PLoS One, 2013)
BACKGROUND: Intracerebral hemorrhage (ICH) is a common and devastating form of cerebrovascular disease. In ICH, gender differences in outcomes remain relatively understudied but have been examined in other neurological ...
Fibroblast growth factor 23 is not associated with and does not induce arterial calcification.
(Kidney international, 2013-06)
Elevated fibroblast growth factor 23 (FGF23) is associated with cardiovascular disease in patients with chronic kidney disease. As a potential mediating mechanism, FGF23 induces left ventricular hypertrophy; however, its ...